VIALE, GIUSEPPE
VIALE, GIUSEPPE
Dipartimento di Oncologia ed Emato-Oncologia
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial
2023 D. Serrano, S. Gandini, P. Thomas, K.D. Crew, N.B. Kumar, L.A. Vornik, J.J. Lee, P. Veronesi, G. Viale, A. Guerrieri-Gonzaga, M. Lazzeroni, H. Johansson, M. D'Amico, F. Guasone, S. Spinaci, B. Bertelsen, G. Mellgren, I. Bedrosian, D. Weber, T. Castile, E. Dimond, B.M. Heckman-Stoddard, E. Szabo, P.H. Brown, A. Decensi, B. Bonanni
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
2023 L. Ferrando, A. Vingiani, A. Garuti, C. Vernieri, A. Belfiore, L. Agnelli, G. Dagrada, D. Ivanoiu, G. Bonizzi, E. Munzone, L. Lippolis, M. Dameri, F. Ravera, M. Colleoni, G. Viale, L. Magnani, A. Ballestrero, G. Zoppoli, G. Pruneri
TMEM123 a key player in immune surveillance of colorectal cancer
2023 E. Pesce, C. Cordiglieri, M. Bombaci, S. Eppenberger-Castori, S. Oliveto, C. Manara, M. Crosti, C. Ercan, M. Coto, A. Gobbini, S. Campagnoli, T. Donnarumma, M. Martinelli, V. Bevilacqua, E. De Camilli, P. Gruarin, M.L. Sarnicola, E. Cassinotti, L. Baldari, G. Viale, S. Biffo, S. Abrignani, L.M. Terracciano, R. Grifantini
Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies
2023 C. Pescia, E. Guerini-Rocco, G. Viale, N. Fusco
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis
2022 N. Bianco, M. Milano, E. Pagan, C. Oriecuia, V. Bagnardi, E.G. Rocco, G.I. Santomauro, G. Peruzzotti, M. Colleoni, G. Viale
Advances and controversies in management of breast ductal carcinoma in situ (DCIS)
2022 G. Farante, A. Toesca, F. Magnoni, G. Lissidini, J. Vila, M. Mastropasqua, G. Viale, S. Penco, E. Cassano, M. Lazzeroni, B. Bonanni, M.C. Leonardi, F. Ripoll-Orts, G. Curigliano, R. Orecchia, V. Galimberti, P. Veronesi
Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status
2022 J. Rüschoff, M. Friedrich, I. Nagelmeier, M. Kirchner, L.M. Andresen, K. Salomon, B. Portier, S.T. Sredni, H.U. Schildhaus, B. Jasani, M. Grzelinski, G. Viale
Pathology after neoadjuvant treatment – How to assess residual disease
2022 G. Viale, N. Fusco
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
2022 L. Gianni, C.S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, G. Bianchini, S. Russo, E.M. Ciruelos, R. Greil, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, I. Maffeis, P. Valagussa, G. Viale
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
2022 B. Acs, S.C.Y. Leung, K.M. Kidwell, I. Arun, R. Augulis, S.S. Badve, Y. Bai, A.L. Bane, J.M.S. Bartlett, J. Bayani, G. Bigras, A. Blank, H. Buikema, M.C. Chang, R.L. Dietz, A. Dodson, S. Fineberg, C.M. Focke, D. Gao, A.M. Gown, C. Gutierrez, J. Hartman, Z. Kos, A.-. Laenkholm, A. Laurinavicius, R.M. Levenson, R. Mahboubi-Ardakani, M.G. Mastropasqua, S. Nofech-Mozes, C.K. Osborne, F.M. Penault-Llorca, T. Piper, M.A. Quintayo, T.T. Rau, S. Reinhard, S. Robertson, R. Salgado, T. Sugie, B. van der Vegt, G. Viale, L.A. Zabaglo, D.F. Hayes, M. Dowsett, T.O. Nielsen, D.L. Rimm
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
2022 E. Guerini-Rocco, G. Botti, M.P. Foschini, C. Marchio, M.G. Mastropasqua, G. Perrone, E. Roz, A. Santinelli, I. Sassi, V. Galimberti, L. Gianni, G. Viale
The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point
2022 L. Kalinowski, G. Viale, S. Domchek, A. Tutt, P.C. Lucas, S.R. Lakhani
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 K. Venetis, E. Crimini, E. Sajjadi, C. Corti, E. Guerini-Rocco, G. Viale, G. Curigliano, C. Criscitiello, N. Fusco
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy
2022 S. Pece, I. Sestak, F. Montani, M. Tillhon, P. Maisonneuve, S. Freddi, K. Chu, M. Colleoni, P. Veronesi, D. Disalvatore, G. Viale, R. Buus, J. Cuzick, M. Dowsett, P.P. Di Fiore
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features
2022 N. Fusco, E. Sajjadi, K. Venetis, M. Ivanova, S. Andaloro, E. Guerini-Rocco, E. Montagna, P. Caldarella, P. Veronesi, M. Colleoni, G. Viale
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one- carbon metabolism in breast cancer
2022 M.G. Filippone, D. Gaglio, R. Bonfanti, F.A. Tucci, E. Ceccacci, R. Pennisi, M. Bonanomi, G. Jodice, M. Tillhon, F. Montani, G. Bertalot, S. Freddi, M. Vecchi, A. Taglialatela, M. Romanenghi, F. Romeo, N. Bianco, E. Munzone, F. Sanguedolce, G. Vago, G. Viale, P.P. Di Fiore, S. Minucci, L. Alberghina, M. Colleoni, P. Veronesi, D. Tosoni, S. Pece
Standard operating procedures for biobank in oncology
2022 G. Bonizzi, L. Zattoni, M. Capra, C. Cassi, G. Taliento, M. Ivanova, E. Guerini-Rocco, M. Fumagalli, M. Monturano, A. Albini, G. Viale, R. Orecchia, N. Fusco
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130
2022 S.S. Badve, F. Penault-Llorca, J.S. Reis-Filho, R. Deurloo, K.P. Siziopikou, C. D'Arrigo, G. Viale
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
2022 L. Gianni, M. Colleoni, G. Bisagni, M. Mansutti, C. Zamagni, L. Del Mastro, S. Zambelli, G. Bianchini, A. Frassoldati, I. Maffeis, P. Valagussa, G. Viale